Avadel Receives Unsolicited Proposal from Lundbeck

Impact · against what's priced in

Avadel shares face immediate upward pressure as a new unsolicited bid from Lundbeck ($23.00) offers a higher potential payout than the existing Alkermes agreement ($20.00). Alkermes faces increased execution risk and potential cost increases if it seeks to protect the deal, while Lundbeck's move is a strategic entry into the asset.

AVDL+0.80

No priced-in read yet

In context

The proposal from Lundbeck for up to $23.00 per share represents a material increase over the existing $20.00 per share agreement with Alkermes.

Read from the article alone

• biotech
• healthcare
• m and a
• pharmaceuticals
• ALKS
• AVDL
• acquisition
• cvr
• superior proposal
• unsolicited proposal

Search tags